Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy

Contributed by: Business Wire

Tags

FDA
Health Technology
Data Management
Manufacturing
Technology
Pharmaceutical
Apps/Applications
Oncology
Infectious Diseases
Clinical Trials
Other Manufacturing
Biotechnology
Science
Software
Research
Health
Gate2Brain

More Like This

PR Newswire associated0

Alveolus Bio Secures Strategic Investment from Shilpa Medicare to Advance Groundbreaking Pulmonary Therapeutics

PR Newswire associated0

SteinCares and Shilpa Biologicals Strike into Licensing Agreement to Expand Access to Biosimilars Across Latin America

Chiesi Group Enters into Worldwide Licensing Agreement with Key2Brain AB to Advance Blood-Brain Barrier-Crossing Therapies for Lysosomal Storage Disorders

PR Newswire associated0

ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases

PR Newswire associated0

A Global Milestone in Innovative Pancreatic Cancer Therapy

Business Wire logo

BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor

ACCESSWIRE logo

CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024

Sironax Grants Novartis Exclusive Option to Acquire its Brain Delivery Platform While Retaining Rights to Advance Selected Therapeutic Assets